An article by the NICE group presented their 30 years experiences in treating ocular tumors with proton therapy. This article highlighted the fact that 6684 patients treated at the facility between 1991 and 2020. Excellent tumor control rates (∼95%), vision preservation and limited toxicity rates have been achieved. Very details were presented and discussed in this paper in regard to the beam line characteristics, dosimetric, microdosimetric and radiobiological consideration, patient and tumor-customization, process of PT planningand delivery. In conclusion, the authors affirm the efficacy and safety in managing ocular tumors using high beam quality and a high degree of sophistication and patient customization, and suggested that if high-energy PBS machines are to be used in ophthalmic oncology, special efforts are needed to achieve comparable dose distributions as with ocular PT.